Potential Solution To Cetuximab-resistance In Lung Cancers Found In Novel EGFR Antibody

Fri, 26 Jan 2007 10:00 AM EST

... A study conducted at the Dana-Farber Cancer Institute and the Ludwig Center at Dana-Farber/Harvard Medical School now suggests that antibodies binding a particular protein conformation, caused by hyperactivation, might have distinct therapeutic advantages over antibodies, like cetuximab, that bind to wild-type (normal) target proteins. ...